Skip to main content

Advertisement

SpringerLink
Log in

Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups

  • Original Article
  • Published:
World Journal of Urology Aims and scope

Abstract

Purpose

Current pathological and clinical parameters provide important prognostic information. However, they are still limitations for predicting the true malignant potential of a specific cancer. The aim of this study was to validate the predicting role of HER-2 expression and demonstrated that combination of the high-risk factors with HER-2 expression is more valuable for determining which non-muscle-invasive bladder cancer (NMIBC) is more aggressive.

Materials and methods

In total, 238 patients treated by transurethral resection of the bladder tumor were histopathologically confirmed to be NMIBC. Two experienced uropathologists re-reviewed the slides. HER-2 expression was evaluated by immunohistochemistry and scored for intensity and area of staining. The association of HER-2 staining with tumor recurrence and progression was evaluated by univariate and multivariate analyses and Kaplan–Meier survival curves.

Results

In multivariable analyses, HER-2 expression was an independent risk factor for predicting tumor progression (HR 2.64, p = 0.024). Combining the EORTC risk scores with HER-2 expression status led to more accurate prediction of progression, especially in patients with intermediate- and high-risk EORTC scores (p < 0.0001, log-rank test).

Conclusions

HER-2 positivity is prognostic for predicting progression to muscle invasion in NMIBC. Combination of the high-risk factors with HER-2 expression is more valuable for determining which NMIBC is more aggressive.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Parkin MD, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  2. Babjuk M et al (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59:997–1008

    Article  PubMed  Google Scholar 

  3. Kurth KH et al (1995) Factors affecting recurrence and progression in superficial bladder tumors. Eur J Cancer 31A:1840–1846

    Article  CAS  PubMed  Google Scholar 

  4. Allard P et al (1998) The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 81:692–698

    Article  CAS  PubMed  Google Scholar 

  5. Soloway MS (2007) It is time to abandon the “superficial” in bladder cancer. Eur Urol 52:1564–1565

    Article  PubMed  Google Scholar 

  6. Bryan RT, Wallace DM (2002) ”Superficial” bladder cancer—time to uncouple pT1 tumours from pTa tumours. BJU Int 90:846–852

    Article  CAS  PubMed  Google Scholar 

  7. Sylvester RJ et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–477

    Article  PubMed  Google Scholar 

  8. Ding Weihong et al (2014) Are EORTC risk tables suitable for Chinese patients with non-muscle-invasive bladder cancer? Cancer Epidemiol 38:157–161

    Article  PubMed  Google Scholar 

  9. Sylvester RichardJ (2011) How well can you actually predict which non-muscle-invasive bladder cancer patients will progress? Eur Urol 60:431–434

    Article  PubMed  Google Scholar 

  10. King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974–976

    Article  CAS  PubMed  Google Scholar 

  11. Olayioye MA et al (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159–3167

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Yarden Y (2001) Biology of HER2 and its importance in breast cancer. Oncology 61(Suppl. 2):1–13

    Article  CAS  PubMed  Google Scholar 

  13. Sato K et al (1992) An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 70:2493–2498

    Article  CAS  PubMed  Google Scholar 

  14. Chow NH et al (2001) Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 7:1957–1962

    CAS  PubMed  Google Scholar 

  15. Gandour-Edwards R et al (2002) Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 95:1009–1015

    Article  CAS  PubMed  Google Scholar 

  16. Latif Z et al (2003) HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 89:1305–1309

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Latif Z et al (2004) HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 40:56–63

    Article  CAS  PubMed  Google Scholar 

  18. Coogan CL et al (2004) HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 63:786–790

    Article  PubMed  Google Scholar 

  19. Kruger S et al (2005) Protein expression and gene copy number analysis of topoisomerase 2a, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder—a multitissue array study with prognostic implications. Anticancer Res 25(1A):263–271

    PubMed  Google Scholar 

  20. Kolla SB et al (2008) Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol 40:321–327

    Article  PubMed  Google Scholar 

  21. Kassouf W et al (2008) Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol 179:353–358

    Article  PubMed Central  PubMed  Google Scholar 

  22. Liedberg F et al (2008) Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urol Oncol 26:17–24

    Article  CAS  PubMed  Google Scholar 

  23. Bolenz C et al (2010) Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int 106:1216–1222

    Article  PubMed  Google Scholar 

  24. Lammers RianneJM, Witjes Alfred (2011) Discussion on the influence of HER2 status on the clinical outcome of bladder cancer continues. Expert Rev Anticancer Ther 11:853–858

    Article  CAS  PubMed  Google Scholar 

  25. Greene FL et al (2002) AJCC cancer staging Manual, 6th edn. Springer, New York, p 2002

    Book  Google Scholar 

  26. Chen Z et al (2012) The 1973 WHO classification is more suitable than the 2004 WHO classification for predicting prognosis in non-muscle-invasive bladder cancer. PLoS One 7:e47199. doi:10.1371/journal.pone.0047199

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Schrier BP et al (2004) Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumors and implications for therapy. Eur Urol 45:292–296

    Article  PubMed  Google Scholar 

  28. Chen PC, Yu HJ, Chang YH, Pan CC (2013) Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. J Clin Pathol 66:113–119

    Article  PubMed  Google Scholar 

  29. Olsson H, Fyhr IM, Hultman P, Jahnson S (2012) HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder. Scand J Urol Nephrol 46:102–107

    Article  CAS  PubMed  Google Scholar 

  30. Lae M et al (2010) Assessing HER-2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 21:815–819

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Denzinger S et al (2008) Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 53:146–152

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This research was supported by National Natural Science Foundation of China (Grant No. 81372756), and role of the funding source is in the study design, in the collection, and analysis and interpretation of data. The authors thank Qinxin Wang for the help in data collection process.

Conflict of interest

None.

Ethical standard

The study was approved by the Institute Research Medical Ethics Committee of Fudan University School of Medicine. Data were analyzed anonymously, and no informed consent was obtained for use of retrospective paraffin sections from the patients, since this was not deemed necessary by the ethics committee, who waived the need for consent.

Author information

Author notes

    Authors and Affiliations

    1. Department of Urology, Huashan Hospital, Fudan University, No. 12 Middle Urumqi Road, Shanghai, 200040, China

      Weihong Ding, Shijun Tong, Yuancheng Gou, Chuanyu Sun, Ke Xu, Guowei Xia & Qiang Ding

    2. Department of Pathology, Huashan Hospital, Fudan University, Shanghai, 200040, China

      Hong Wang & Zhongqing Chen

    3. Department of Biostatistics and Social Medicine, School of Public Health, Fudan University, Shanghai, 200032, China

      Jun Tan

    Authors
    1. Weihong Ding
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Shijun Tong
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Yuancheng Gou
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Chuanyu Sun
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Hong Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Zhongqing Chen
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Jun Tan
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Ke Xu
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Guowei Xia
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Qiang Ding
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Ke Xu.

    Additional information

    Weihong Ding and Shijun Tong have contributed equally to this study.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Ding, W., Tong, S., Gou, Y. et al. Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups. World J Urol 33, 1951–1957 (2015). https://doi.org/10.1007/s00345-015-1557-9

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00345-015-1557-9

    Keywords

    Search

    Navigation